메뉴 건너뛰기




Volumn 22, Issue 1, 2014, Pages 277-284

Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: Design, synthesis and biological evaluation

Author keywords

Angiogenesis; Biphenyl scaffold; Urea moiety; VEGFR 2 inhibitor

Indexed keywords

BIPHENYL DERIVATIVE; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 4 (2 MORPHOLIN 4 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 4 (2 PIPERIDIN 1 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 4 (3 MORPHOLIN 4 YLPROPOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 5 (2 MORPHOLIN 4 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 5 (2 PIPERIDIN 1 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [2 METHYL 5 (3 MORPHOLIN 4 YLPROPOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 (2 MORPHOLIN 4 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 (3 MORPHOLIN 4 YLPROPOXY)PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [2 (DIETHYLAMINO)ETHOXY] 2 METHYLPHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [2 (DIETHYLAMINO)ETHOXY]PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [2 (DIMETHYLAMINO)ETHOXY] 2 METHYLPHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [2 (DIMETHYLAMINO)ETHOXY] PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [3 (DIMETHYLAMINO)PROPOXY] 2 METHYLPHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [4 [3 (DIMETHYLAMINO)PROPOXY]PHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [5 [2 (DIETHYLAMINO)ETHOXY] 2 METHYLPHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [5 [2 (DIMETHYLAMINO)ETOXY] 2 METHYLPHENYL]UREA; N (4' ACETYL 3',5,6 TRIMETHOXYBIPHENYL 3 YL) N' [5 [3 (DIMETHYLAMINO)PROPOXY] 2 METHYLPHENYL]UREA; N [4 [2 (DIETHYLAMINO)ETHOXY] 2 METHYLPHENYL] N' [4' [N HYDROXYETHANIMIDOYL] 3',5,6 TRIMETHOXYBIPHENYL 3 YL]UREA; N [4 [2 (DIMETHYLAMINO)ETHOXY] 2 METHYLPHENYL] N' [4' [N HYDROXYLETHANIMIDOYL] 3',5,6 TRIMETHOXYBIPHENYL 3 YL]UREA; N [4 [3 (DIMETHYLAMINO)PROPOXY] 2 METHYLPHENYL] N' [4' [N HYDROXYETHANIMIDOYL] 3',5,6 TRIMETHOXYBIPHENYL 3 YL]UREA; N [4' [N HYDROXYETHANIMIDOYL] 3',5,6 TRIMETHOXYBIPHENYL 3 YL] N' [2 METHYL 4 (2 PIPERIDIN 1 YLETHOXY)PHENYL]UREA; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

EID: 84891492233     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.11.027     Document Type: Article
Times cited : (54)

References (24)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.